JungHyun Lee1, Kun Sei Lee2, Hyeongsu Kim1, Hyoseon Jeong1, Min-Jung Choi1, Hai-Won Yoo1, Tae-Hwa Han3, Hyunjung Lee4. 1. Department of Preventive Medicine, School of Medicine, Konkuk University, Neungdongro 120, Gwangjin-gu, Seoul, 05029, Korea. 2. Department of Preventive Medicine, School of Medicine, Konkuk University, Neungdongro 120, Gwangjin-gu, Seoul, 05029, Korea. kunsei.lee@kku.ac.kr. 3. Health IT Center, College of Medicine, Yonsei University, Seoul, Korea. 4. Department of Nursing, College of Nursing, Konyang University, Daejeon, Korea.
Abstract
OBJECTIVES: This study evaluated the incidence of colorectal cancer (CRC) according to the number of metabolic syndrome (MetS) components. METHODS: Using health checkup and insurance claims data of 6,365,409 subjects, the occurrence of CRC according to stage of MetS by sex was determined from the date of the health checkup in 2009 until December 31, 2018. RESULTS: Cumulative incidence rates (CIR) of CRC in men and women was 3.9 and 2.8 per 1000 (p < 0.001), respectively. CIR of CRC for the normal, pre-MetS, and MetS groups in men was 2.6, 3.9, and 5.5 per 1000 (p < 0.001) and CIR in women was 2.1, 2.9, and 4.5 per 1000 (p < 0.001), respectively. Compared with the normal group, the hazard ratio (HR) of CRC for the pre-MetS group was 1.25 (95% CI 1.17-1.33) in men and 1.09 (95% CI 1.02-1.17) in women, and the HR of CRC for the MetS group was 1.54 (95% CI 1.43-1.65) in men and 1.39 (95% CI 1.26-1.53) in women after adjustment. CONCLUSIONS: We found that MetS is a risk factor for CRC in this study. Therefore, the prevention and active management of MetS would contribute to the prevention of CRC.
OBJECTIVES: This study evaluated the incidence of colorectal cancer (CRC) according to the number of metabolic syndrome (MetS) components. METHODS: Using health checkup and insurance claims data of 6,365,409 subjects, the occurrence of CRC according to stage of MetS by sex was determined from the date of the health checkup in 2009 until December 31, 2018. RESULTS: Cumulative incidence rates (CIR) of CRC in men and women was 3.9 and 2.8 per 1000 (p < 0.001), respectively. CIR of CRC for the normal, pre-MetS, and MetS groups in men was 2.6, 3.9, and 5.5 per 1000 (p < 0.001) and CIR in women was 2.1, 2.9, and 4.5 per 1000 (p < 0.001), respectively. Compared with the normal group, the hazard ratio (HR) of CRC for the pre-MetS group was 1.25 (95% CI 1.17-1.33) in men and 1.09 (95% CI 1.02-1.17) in women, and the HR of CRC for the MetS group was 1.54 (95% CI 1.43-1.65) in men and 1.39 (95% CI 1.26-1.53) in women after adjustment. CONCLUSIONS: We found that MetS is a risk factor for CRC in this study. Therefore, the prevention and active management of MetS would contribute to the prevention of CRC.
Authors: Eun Ju Ko; Eo Jin Kim; Hye Jung Cho; Jisu Oh; Han Sung Park; Chang Soo Ryu; Jung Oh Kim; Hak Hoon Jun; So Young Chong; Jong Woo Kim; Nam Keun Kim Journal: Genes Genomics Date: 2022-04-04 Impact factor: 2.164
Authors: Sophia Harlid; Bethany Van Guelpen; Conghui Qu; Björn Gylling; Elom K Aglago; Efrat L Amitay; Hermann Brenner; Daniel D Buchanan; Peter T Campbell; Yin Cao; Andrew T Chan; Jenny Chang-Claude; David A Drew; Jane C Figueiredo; Amy J French; Steven Gallinger; Marios Giannakis; Graham G Giles; Marc J Gunter; Michael Hoffmeister; Li Hsu; Mark A Jenkins; Yi Lin; Victor Moreno; Neil Murphy; Polly A Newcomb; Christina C Newton; Jonathan A Nowak; Mireia Obón-Santacana; Shuji Ogino; John D Potter; Mingyang Song; Robert S Steinfelder; Wei Sun; Stephen N Thibodeau; Amanda E Toland; Tomotaka Ugai; Caroline Y Um; Michael O Woods; Amanda I Phipps; Tabitha Harrison; Ulrike Peters Journal: Int J Cancer Date: 2022-04-22 Impact factor: 7.316